AN INITIATION of Legislation to allow under state law the medical use of marihuana; to provide protections for the medical use of marihuana; to provide for a system of registry identification cards for qualifying patients and primary caregivers; to impose a fee for registry application and renewal; to make an appropriation; to provide for the promulgation of rules; to provide for the administration of this act; to provide for enforcement of this act; to provide for affirmative defenses; and to provide for penalties for violations of this act.
Qualifying patient or primary caregiver; arrest, prosecution, or penalty prohibited; conditions; privilege from arrests; presumption; compensation; physician subject to arrest, prosecution, or penalty prohibited; marihuana paraphernalia; person in presence or vicinity of medical use of marihuana; registry identification card issued outside of department; sale of marihuana as felony; penalty; marihuana-infused product.
Registered qualifying patient or registered primary caregiver; arrest, prosecution, or penalty, or denial of right or privilege prohibited; conditions.
A new advisory bulletin has been issued by the Bureau of Medical Marihuana.
Proficiency Testing Guidelines for Safety Compliance Facilities.
Released July 5, 2018
The Medical Marihuana Facilities Licensing Act (MMFLA) and the May 30, 2018 Emergency Rules require the Dept of Licensing and Regulatory Affairs to establish a proficiency testing program and designate safety compliance facility participation.
A safety compliance facility shall analyze proficiency test (PT) samples using the same procedures with the same number of replicate analyses, standards, testing analysts and equipment as used for marihuana product testing. The following proficiency testing must be performed by Safety Compliance Facilities (SCFs) annually:
SCFs will need to complete one set of PT samples for all tests on their scope of accreditation.
Proficiency test results must be conveyed as numerical accuracy percentages, not simply as PASS/FAIL results. Actual PASS/FAIL results must be calculated based on accuracy thresholds generated by reproducibility studies specific to each assay.
Safety Compliance Facilities may use any ISO 17043 accredited laboratory for their testing needs. There are several ISO 17043 accredited laboratories where samples can be purchased, including The Emerald Test, NSI Lab Solutions, Sigma-Aldrich and Absolute Standards Inc.
For parameters where there are currently no commercially available PT samples, SCFs should send samples (as blind samples) to another licensed SCF who performs testing by the same or similar methodology. The results should then be compared. A passing grade for the PT requires a score of at least 80%.
Copies of all proficiency testing (both acceptable and unacceptable) results need to be sent to the department for review via email: LARA-BMMR-Enforcement@michigan.gov. Please indicate in the subject line “Proficiency Testing Results for Review-SCF Name.”
It is also available at the following link…PDF Document
The Michigan Medical Marihuana Licensing system is evolving into a confusing, mind-blowing regulatory nightmare.
Medical marijuana has been legal in this state for 10 years, and the Medical Marihuana Facilities Licensing Act was passed in September 2016. Now, consider that, after all that time, in a couple of weeks (on June 15), according to the Bureau of Medical Marihuana Regulation (BMMR), any currently operating marijuana facility must have a state license in order to legally stay open.
That’s fine, except the state hasn’t given out any licenses as of this writing.
According to David Harns, public information officer with the state Bureau of Licensing and Regulatory Affairs (LARA), “We expect to be handing out licenses within the next few weeks. Most likely at the June 11 meeting [of the Medical Marihuana Licensing Board].”
Talk about running things up until the last minute!
The BMMR — could this be an acronym for bummer? — created this whole scenario by setting the deadlines and setting up an application process that is so cumbersome to all involved that none of this can get done by the self-imposed deadline.
That means dispensaries, provisioning centers, or whatever you want to call them, may or may not have licenses to operate come June 15. Not only that, any licenses handed out may go to facilities that are not currently open. That would create a huge gap in service to patients while newly licensed facilities ramp up their operations.
If the state were interested in patients having uninterrupted access to medication, it might make sense to move the deadline back a little. After all, it is the BMMR that set up a bureaucracy involving so much red tape that it was impossible for applications to be processed in the allotted time.
According to Harns, the deadline is not moving. And that’s where the real mind-fuck kicks in. Harns says that if already operating facilities are showing a “good faith” effort to become licensed, they don’t need to worry about LARA. A recent advisory from LARA read: “While the ultimate licensure decision is made by the Medical Marihuana Licensing Board, LARA does not currently intend to issue cease and desist letters, or refer to law enforcement” marijuana stores that continue to operate past the deadline.
LARA’s decision not to go after unlicensed stores that are making a good faith effort to become licensed is sensible; it’s like moving the deadline back — by not enforcing it.
But then LARA points out that LARA is not making the decision about who gets licenses. So if you decide to continue operating, the Licensing Board might hold it against you.
“The Licensing Board has ultimate authority,” Harns says. “They may choose to consider unlicensed activity when looking at the licensing criteria.”
Basically LARA is saying that there’s a deadline, but if you don’t adhere to it, we don’t care, but those other people over there who actually make the decision on whether you get a license might care — or they might not.
That’s a hell of an advisory.
Not only is that a confusing pile of hooey, it sets up the possibility for unequal application of the rules. If the Licensing Board can choose to consider that in one case and not in another, then that sets up legal challenges that will last forever. If they couldn’t decide if “unlicensed activity” counts against an applicant after all this time, then the consideration should be thrown out the window.
Even at this late juncture, Harns threw out a lot of “the board may do this” or “the board may do that” scenarios, finishing with, “Those are a lot of mays. I can’t speak definitively for those board members.”
That’s a lot of uncertainty for everybody concerned, especially patients. For instance, once growing licenses get handed out, it is a fact of nature that it takes several months to grow a plant to maturity. Add on some time for transporting and processing and inspecting, and it means that it will probably be 2019 before this whole thing really gets rolling.
Harns points to the caregiver system to keep patients supplied. “That has not changed at all,” he says.
That’s nice. But, first of all, there are a lot of people who thought they were going to grow their own marijuana who have thrown in the towel because getting consistent results and maintaining a constant supply is harder than they thought it would be. Second, anyone that needs oil for seizures or cancer treatments depends on a much more sophisticated process than the average caregiver can handle. And, third, this stuff has been legal here for a decade, dude — get it together and roll out the system!
The whole thing stinks of a state government that has not made a good faith effort to make this system work and won’t move forward without watchdogs nipping at their heels. It’s taken an army of activists and lawyers to get things to this point.
It also seems that it’s going to get uglier before it gets better, as we see who will actually get licenses and who will get their dreams smashed on the rocks.
CBD is marijuana
CBD (cannabidiol), one of the many compounds in marijuana, has developed a high profile the past several years due to its usefulness in reducing seizures for epilepsy patients. It’s been marketed by some companies as legal, because it’s extracted from hemp, the strain of cannabis used to make textiles and other products. It’s also been embraced as “the part of marijuana that doesn’t get you high.”
On May 11, LARA put out an advisory that erased any doubt you may have about our state government’s attitude toward CBD. In part, the advisory read: “The possession, purchase, or sale of marihuana or any marihuana product — including CBD — must be done in compliance with the MMMA and MMFLA.”
A review panel on Friday 5-4-18 recommended adding 10 new conditions to the list of ailments for approval for medical marijuana use. The recommended additions are…
Obsessive compulsive disorder
Arthritis
Rheumatoid arthritis
Spinal cord injury
Inflammatory bowel disease
Ulcerative colitis
Parkinson’s
Tourette Syndrome
Autism
Chronic pain
A Michigan regulator will consider an advisory board’s recommendation to add autism and other conditions to a list of allowable medical conditions for the use of marijuana.
Shelly Edgerton who is The Department of Licensing and Regulatory Affairs Director has until July 10, 2018 to make a decision on nine of the recommendations and until Aug. 6 to make a decision on another.
A previous director in 2015 rejected a recommendation to allow marijuana use for autism.
Marijuana is allowed to relieve the side effects of cancer and other conditions. Only post-traumatic stress disorder has been added since 2008.
Location:
Williams Building 1st Floor Auditorium
525 W Ottawa St, Lansing, MI 48933
AGENDA
The public hearing is for the Medical Marihuana Review Panel (Review Panel) to review
petitions to include a particular medical condition or treatment to the list of debilitating
medical conditions pursuant to the Michigan Medical Marihuana Act, 2008 IL 1, MCL
333.26421 to 333.26430 (MMMA).
The petitions submitted to the Review Panel under the MMMA are as follows: anxiety,
depression, obsessive compulsive disorder, panic attacks, schizophrenia, social anxiety
disorder, arthritis, rheumatoid arthritis, brain injury, spinal cord injury, asthma, diabetes,
colitis, gastric ulcer, inflammatory bowel disease, ulcerative colitis, organ transplant, non severe and non-chronic pain, Parkinson’s, Tourette’s syndrome, autism, and chronic pain.
And any other business properly before the Review Panel.
The meeting site and parking are accessible. To enhance accessibility for everyone, individuals attending the meeting
are requested to refrain from using heavily scented personal care products. People with disabilities requiring additional
accommodations to participate in the meeting should call Kelly Kronner at (517) 284-8584. LARA is an equal
opportunity employer/program.